Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

• ClinicalTrials.gov Identifier: NCT05558007
• Recruitment Status: Recruiting
• First Posted: September 28, 2022
• Last Update Posted: March 12, 2024
• Sponsor: Biozeus Biopharmaceutical S.A.
• Information provided by (Responsible Party): Biozeus Biopharmaceutical S.A.

Tracking Information

• First Submitted Date: September 22, 2022
• First Posted Date: September 28, 2022
• Last Update Posted Date: March 12, 2024
• Actual Study Start Date: November 22, 2023
• Estimated Primary Completion Date: August 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 29, 2023)

Change in Assisted Erectile Function [ Time Frame: From up to 30 days before Baseline, Baseline, 30 days, 60 days ]

Measurement of the ability to to have an erection that allows sexual intercourse, under use of medication. This will be assessed by using the IIEF questionnaire, domain A (erectile function section) (IIEF-EF).

Original Primary Outcome Measures (submitted: September 23, 2022)

• Change in Assited Erectile Function [ Time Frame: Day before Baseline, Baseline, 30 days, 60 days ]
  Measurement of the ability to to have an erection that allows sexual intercourse, under use of medication. This will be assessed by using the IIEF questionnaire, domain A (erectile function section) (IIEF-EF).
• Change rate of successful vaginal intercourse [ Time Frame: Day before Baseline, Baseline, 30 days, 60 days ]
  Rate of successful vaginal intercourse will be assessed through question 3 of the SEP (Sexual Encouter Profile) questionnaire.
• Change in quality of sexual intercourse [ Time Frame: 30 days, 60 days ]
  Quality of sexual intercourse, through the EDITS questionnaire (Erectile Dysfunction Inventory of Treatment Satisfaction);
• Change in penile extension [ Time Frame: Baseline, 30 days, 60 days ]
  Penile extension, measured with a ruler.

Current Secondary Outcome Measures (submitted: October 24, 2023)

• Change in successful vaginal intercourse rate [ Time Frame: From up to 30 days before Baseline, Baseline, 30 days, 60 days ]
  Rate of successful vaginal intercourse will be assessed through question 3 of the SEP (Sexual Encouter Profile) questionnaire.
• Change in quality of sexual intercourse [ Time Frame: 30 days, 60 days ]
  Quality of sexual intercourse, through the EDITS questionnaire (Erectile Dysfunction Inventory of Treatment Satisfaction);
• Change in penile extension [ Time Frame: Baseline, 30 days, 60 days ]
  Penile extension, measured with a ruler.
• Penile Blood flow increase [ Time Frame: From up to 30 days before Baseline, Baseline, 30 days, 60 days ]
  Increased blood flow, assessed by peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistivity index (RI) assessed by Doppler examination;
• Adverse effects report [ Time Frame: Baseline 30 days, 60 days and 75 days ]
  Adverse effects evaluation of compound use and application
• Physical examination of the applied region [ Time Frame: From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days ]
  Number of participants with abnormal physical exam findings in the applied region
• Change in SBP [ Time Frame: From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days ]
  Change in Systolic Blood Pressure
• Change in DBP [ Time Frame: From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days ]
  Change in Diastolic Blood Pressure
• Change in Heart Rate (HR) [ Time Frame: From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days ]
  Change in Heart Rate
• Basal chest electrocardiogram (ECG). [ Time Frame: From up to 30 days before Baseline, 30 days and 60 days ]
  Number of participants with abnormal ECG test results
• Blood evaluation [ Time Frame: From up to 30 days before Baseline, and 60 days ]
  Number of participants with abnormal laboratory test results
• Urine evaluation [ Time Frame: From up to 30 days before Baseline, and 60 days ]
  Number of participants with abnormal laboratory test results

Original Secondary Outcome Measures (submitted: September 23, 2022)

• Adverse effects report [ Time Frame: 30 days, 60 days and 75 days ]
  Adverse effects evaluation of compound use and application
• Physical examination of the applied region [ Time Frame: Day before Baseline, 30 days, 60 days and 75 days ]
  Number of participants with abnormal physical exam findings in the applied region
• Change in SBP [ Time Frame: Day before Baseline, Baseline, 30 days, 60 days and 75 days ]
  Change in Systolic Blood Pressure
• Change in DBP [ Time Frame: Day before Baseline, Baseline, 30 days, 60 days and 75 days ]
  Change in Diastolic Blood Pressure
• Change in Heart Rate (HR) [ Time Frame: Day before Baseline, Baseline, 30 days, 60 days and 75 days ]
  Change in Heart Rate
• Basal chest electrocardiogram (ECG). [ Time Frame: Day before Baseline, 30 days and 60 days ]
  Number of participants with abnormal ECG test results
• Blood evaluation [ Time Frame: Day before Baseline and 60 days ]
  Number of participants with abnormal laboratory test results

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
• Official Title: Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A In A Gel Applied in Patients That Performed Radical Prostatectomy
• Brief Summary: To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.

Detailed Description

Prostate cancer remains one of the most prevalent cancer in men. For its treatment, recent technological advances demonstrate that the most effective treatment is the Radical Prostatectomy (RP) procedure. However, although curative for Prostate Cancer, can result in damage to the cavernosal nerves.

The cavernosal autonomic nerves travel posterolaterally to the prostate to enter the penis and regulate blood flow and hence erection. Thus, damage caused by RP will affect NO tissue release and blood flow regulation, causing erectile dysfunction.

BZ371A has the ability to restore local blood flow regulation by a new and innovative mechanism of action and, therefore, has potential to be a supportive therapy for RP patients (restoring the erectile function).

Thus, this study aims to evaluate efficacy, safety and tolerabilty of BZ371A on the recovery of erectile function of patients that were underwent Radical Prostatectomy.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment

Condition

• Erectile Dysfunction Following Radical Prostatectomy
• Erectile Dysfunction
• Prostate Cancer
• Radical Prostatectomy

Intervention

• Drug: Tadalafil 5mg
  Daily oral administration of tadalafil 5mg
  Other Name: Tadalafil
• Drug: BZ371A
  Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
• Drug: Oral Placebo
  Oral administration of a placebo pill
• Drug: Topical Placebo
  Topical application of 1.5 mL of placebo

Study Arms

• Active Comparator: Daily oral Tadalafil 5mg + Topical Placebo
  Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical placebo
  Interventions:

  • Drug: Tadalafil 5mg
  • Drug: Topical Placebo
• Experimental: Daily oral placebo + topical BZ371A
  Patient that underwent Radical Prostatectomy will receive daily oral placebo and topical BZ371A
  Interventions:

  • Drug: BZ371A
  • Drug: Oral Placebo
• Active Comparator: Daily oral Tadalafil 5mg + topical BZ371A
  Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical BZ371A
  Interventions:

  • Drug: Tadalafil 5mg
  • Drug: BZ371A

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: September 23, 2022): 72
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: September 2024
• Estimated Primary Completion Date: August 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Men between the ages of 40 and 65 years;
2. Exclusive heterosexual men, regardless of race or social class.
3. RP due to prostate cancer without metastasis;
4. RP performed less than 60 days before the screening visit;
5. Erectile function prior to normal RP, defined as IIEF questionnaire with more than 22 points in domain A;
6. Stable sexual partner (more than 2 months prior to RP), and intention to maintain the relationship during the study.
7. Continuous use of 5mg Tadalafil from the 30th up to the 60th day after RP.

Exclusion Criteria:

1. Prostate cancer in TNM stage classified as T3 or T4.
2. Perineal and/or open RP;
3. Necessity of other therapy for prostate cancer than RP, including radiation therapy or hormone therapy;
4. Uncontrolled diabetes at screening visit (HbA1C > 10%);
5. Prior spinal cord injury with lower limb paralysis;
6. Current male hormone use, or hypogonadism, defined by total testosterone below 8 nmol/L (2300 pg/mL) or total testosterone between 8 and 11 nmol/L (2300 and 3170 pg/mL) and free testosterone < 220 pmol/L (< 64 ng/dL);
7. Patients with current depression, characterized by use or need for use of antidepressants.
8. Presence of genital lesions (such as severe penile fibrosis or Peyronie's disease) or active sexually transmitted disease (STD) (such as herpes, gonorrhea, candidiasis, HPV, and others) that impair analysis of local adverse effects on the genitalia;
9. Use of topical medications in the genital region that may interfere in the IP evaluation, as well as in its absorption or drug interaction;
10. Possession of penile prosthesis;
11. History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patient with heart diseases (including history of angina and/or heart failure) and nephropathies;
12. Current use of nitrates, such as propatilnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®, Nitronal®, Tridil®) and isosorbitol dinitrate (Isocord®);ketoconazole; ritonavir; and rifampicin.
13. Findings on ECG and/or laboratory tests that, in the Investigator's criteria, are considered significant and offer risk to the research volunteer's participation or may hinder the study analyses;
14. BP outside the limits considered safe: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg or above 100 mmHg, except situations such as "white coat syndrome";
15. Diseases that can cause priapism, such as sickle cell anemia, multiple myeloma, or leukemia;
16. Histroy of priapism, defined as painful erection from up to 6 hours.
17. Current relevant diarrhea, defined as duration over four weeks, association with abdominal pain or dysabsortive syndrome, or presence of mucus, pus, or blood in the stool;
18. Known hypersensitivity to tadalafil and/or BZ371A;
19. History of symptomatic Lactose intolorence such as: the necessity of enzymatic treatment, abdominal distension or diarrhea when ingesting products or supplements with lactose;
20. Low adhsesion to 5mg Tadalafil use, characterized by the use of <80% of the pills between the 30th and 60th day post PR;.
21. Pregnant or lacting partner.
22. Partner in childbearing age which does not accept to get exposed to the treatment
23. Any disease, condition or physical finding that the Investigator considers significant and that increases the risk of the research subject's participation or may interfere with the results, including severe debilitating illness, presence of cancer other than prostate cancer, severe mental illness persistent medication abuse;

Sex/Gender

• Sexes Eligible for Study: Male

• Ages: 40 Years to 65 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Camilla NR Trindade, PhD; +55(21)2523-9089; camilla.nunes@biozeus.com.br

• Listed Location Countries: Brazil

Administrative Information

• NCT Number: NCT05558007
• Other Study ID Numbers: BZ371CLI004
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Biozeus Biopharmaceutical S.A.
• Original Responsible Party: Same as current
• Current Study Sponsor: Biozeus Biopharmaceutical S.A.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Luiz Otávio Torres, Dr; Hospital Urológica

• PRS Account: Biozeus Biopharmaceutical S.A.
• Verification Date: March 2024